To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
De Novo metastatic breast cancer in males versus females: a Swedish, population-based cohort study
Science for Life Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, Dag Hammarskjoldsvag 20, Uppsala, 751 85, Sweden; Department of Oncology, Uppsala University Hospital, Uppsala, 751 85, Sweden.
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Department of Breast, Endocrine Tumours and Sarcoma, Karolinska Comprehensive Cancer Center, Karolinska University Hospital, Stockholm, Sweden.
Department of Surgical and Perioperative Sciences, Umeå University, Umeå, Sweden; Department of Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Örebro University, School of Medical Sciences. Örebro University Hospital. Science for Life Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, Dag Hammarskjoldsvag 20, Uppsala, 751 85, Sweden; Department of Oncology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.ORCID iD: 0000-0001-6059-0194
2023 (English)In: JNCI cancer spectrum, E-ISSN 2515-5091, Vol. 7, no 4, article id pkad050Article in journal (Refereed) Published
Abstract [en]

Current evidence on de novo metastatic breast cancer (dnMBC) is based on data from women. This Swedish, population-based cohort study compared the incidence over time and prognosis of dnMBC between sexes using data from the National Quality register for Breast Cancer. Joinpoint regression analysis was used to compare incidence trends in all stages (104,733 women, 648 men) and multivariate Cox regression analysis to investigate potential sex disparities in dnMBC prognosis (6005 women, 41 men). For both sexes, increased trends were evident for stages I-II with a stabilizing trend at the later years for women while stage III incidence remained stable. An increased trend for dnMBC in women, and to less extent in men, was observed. No difference in dnMBC overall survival between sexes was observed (HR : 1.24; 95% CI : 0.85-1.81). The comparable features in terms of incidence and prognosis of dnMBC between sexes imply similarities supporting the adoption of common treatment strategies.

Place, publisher, year, edition, pages
Oxford University Press, 2023. Vol. 7, no 4, article id pkad050
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:oru:diva-107481DOI: 10.1093/jncics/pkad050ISI: 001053100300001PubMedID: 37490458Scopus ID: 2-s2.0-85169931765OAI: oai:DiVA.org:oru-107481DiVA, id: diva2:1786492
Available from: 2023-08-09 Created: 2023-08-09 Last updated: 2023-12-08Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Valachis, Antonis

Search in DiVA

By author/editor
Valachis, Antonis
By organisation
School of Medical SciencesÖrebro University Hospital
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 71 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf